Nxera Pharmas QUVIVIQ (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with…
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for…
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
September 29, 2025 19:30 ET | Source: Nxera Pharma Tokyo, Japan and…
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
Pipeline led by a new proprietary oral small molecule GLP-1 agonist and…
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessas Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
July 04, 2025 03:00 ET | Source: Nxera Pharma Tokyo, Japan and…
